Novo Nordisk, Inc. Company Profile

03:02 EDT 4th July 2015 | BioPortfolio

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 29,650 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.


News Articles [432 Associated News Articles listed on BioPortfolio]

Novo-Nordisk mit beeindruckender Performance!

Die Aktien des dänischen Pharmaunternehmens Novo-Nordisk haben seit Anfang Januar eine beeindruckende Performance gezeigt. Novo-Nordisk gehört zu den führenden Herstellern von Diabetes-Arzneimittel...

Novo Nordisk A/S: Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US

Bagsværd, Denmark, 26 March 2015 - Novo Nordisk today announced that the company has decided to submit the prespecified interim analysis of DEVOTE as part of a Class II Resubmission of the New Dru...

Novo Nordisk A/S: Novo Nordisk receives positive opinion from the European regulatory authorities for Saxenda® (liraglutide 3 mg) for the treatment of obesity

Bagsværd, Denmark, 22 January 2014 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinio...

Novo Nordisk invests in haemophilia with Denmark facility

Novo Nordisk is spending around $225 million on a new facility in Kalundborg, Denmark to produce active pharmaceutical ingredients for haemophilia products. The firm says the move will create 100...

Novo Nordisk A/S: Novo Nordisk A/S - Share repurchase programme

Bagsværd, Denmark, 22 June 2015 - On 30 April 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22...

Novo Nordisk A/S: Resolutions from the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 19 March 2015 - Today, Novo Nordisk A/S held its Annual General Meeting, at which the following were adopted: Financial year 2014 and 2015 The Company's audited Annual Report 20...

Novo Nordisk, Baxter clash over hemophilia drug patent

Novo Nordisk on Wednesday rejected claims by Baxter International that its drug used substances developed by the U.S. rival, following the launch this week of a U.S. investigation into possible patent...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 30 January 2015

Bagsvaerd, Denmark, Feb. 2, 2015 (GLOBE NEWSWIRE) -- In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of a...

Drugs and Medications [33 Associated Drugs and Medications listed on BioPortfolio]

Novolin [Novo Nordisk]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Novo Nordisk]

NOVOLIN N Human Insulin Isophane Suspension (recombinant DNA origin) 100 units/mL

Novolin [Novo Nordisk]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Physicians Total Care, Inc.]

Novolin 70/30, 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)

Novolin [Novo Nordisk]

R HUMAN Novolin R Regular, Human Insulin Injection (recombinant DNA origin) USP 100 units/mL

PubMed Articles [287 Associated PubMed Articles listed on BioPortfolio]

Liraglutide for Type 2 diabetes and obesity: a 2015 update.

Subcutaneous liraglutide (Victoza(®), Novo Nordisk) was approved for the treatment of Type 2 diabetes mellitus (T2DM) in Europe in 2009 and in the USA in 2010. In December 2014, liraglutide 3.0 mg wa...

RAMPART: a workflow management system for de novo genome assembly.

The de novo assembly of genomes from whole genome shotgun sequence data is a computationally intensive, multi-stage task and it is not known a priori which methods and parameter settings will produce ...

Trigger Matters: An Ergonomy Analysis of Insulin Pens.

Background: Excessive force required to deliver a set dose of insulin as well as a localization of the push button and its upwards extension may result in significant difficulties to safely perform in...

Maternal and fetal outcome in de novo preeclampsia in comparison to superimposed preeclampsia: a two-year observational study.

Aim: To assess the maternal and fetal outcome in women with de novo preeclampsia (PE) in comparison to superimposed PE. Study design: This was a prospective 2-year observational study carried out at M...

Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission.

Secondary AML (sAML) has a poor prognosis with conventional chemotherapy alone. Allogeneic hematopoietic cell transplantation (HCT) is beneficial for high-risk AML. Data comparing outcomes of transpla...

Clinical Trials [227 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients

The purpose of this study is to investigate and evaluate the effects of different interventions (1.continuous subcutaneous insulin infusion,2.multiple daily injections, 3.anti-hyperglycemi...

Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia

The aim of this study is to test the safety and efficacy of a new algorithm for intensive s.c. insulin injection in medical emergency patients with hyperglycaemia (plasma glucose concentra...

Comparison of 2 NovoFine® Needles on the Reflux of Insulin

This trial is conducted in Europe. This trial aims to ensure that there is no substantial clinically relevant difference between the two Novo Nordisk needles NovoFine® 6 x 0.30 mm and Nov...

Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects

This trial is conducted in Europe. The aim of this clinical trial is to compare the metabolism of a blood-clotting drug (recombinant Factor XIII) produced by two different manufacturers (N...

Evaluating Therapeutic Response to Novo-TTF

This study is to assess the utility of high resolution 3D echo planar magnetic resonance spectroscopy (3D EPSI) in monitoring Novo-TTF response in glioblastoma multiforme (GBM) patients.

Companies [49 Associated Companies listed on BioPortfolio]

Novo A/S

Novo A/S is fully owned by the Novo Nordisk Foundation and is the holding company of the Novo Group. Novo A/S is a private limited liability company and the majority shareholder in the publicly listed...

Novo Nordisk, Inc.

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy...

Novo Nordisk A/S

Novo A/S, the holding company of the Novo Group, is fully owned by the Novo Nordisk Foundation and was established to manage the Foundation's funds and to invest actively in other companies. What make...

Novo Nordisk

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area ...

Novo Nordisk Inc.

More Information about "Novo Nordisk, Inc." on BioPortfolio

We have published hundreds of Novo Nordisk, Inc. news stories on BioPortfolio along with dozens of Novo Nordisk, Inc. Clinical Trials and PubMed Articles about Novo Nordisk, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novo Nordisk, Inc. Companies in our database. You can also find out about relevant Novo Nordisk, Inc. Drugs and Medications on this site too.


Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Latest News Clinical Trials Research Drugs Reports Corporate
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2014 Top 10 biotech and pharmaceutical companies worldwide based on market value in 2014 (in billion U.S. dollars) data Johnson & Johnson, U.S. 2...

Healthcare
Latest News Clinical Trials Research Drugs Reports Corporate
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record